Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
BOOG 2010-02 Stop&Go study
Phase 3 small_molecule completed
Quick answer
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine for Human Epidermal Growth Factor 2 Negative Carcinoma of Breast is a Phase 3 program (small_molecule) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Indication
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed